Fibroblast News and Research

RSS

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.

15 Jun 2011

Linkam tensile stage chosen to control stress in growth of human collagen by the University of Liverpool

Manufacturers temperature controlled microscopy, Linkam Scientific Instruments, have been chosen by the Physics Department of the University of Liverpool to study the effects of controlling stresses applied during the growth of collagen secreted from human fibroblast cells. The research goal of Senior Research Assistant, Dr Caroline Smith, and her colleagues at the University of Liverpool is to advance the treatment of tendon injuries by developing a method of growing oriented human collagen.

From Linkam Scientific Instruments 7 Jun 2011

Histogenics announces acquisition of ProChon Biotech

Histogenics Corporation, a privately held regenerative medicine company, announced today that it has acquired ProChon Biotech, Ltd. in a stock-for-stock exchange.

17 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.

10 May 2011

Cosmofrance introduces Dermasculpt microcannula for painless cosmetic injections

Cosmofrance Inc. introduces Dermasculpt a FDA-approved, FLEXIBLE blunt-tip microcannula for non-bruising & practically painless cosmetic injections.

5 May 2011

Researchers discover strategy that promotes new blood vessel formation

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.

18 Apr 2011

The Wistar Institute, Advaxis enter research collaboration

Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has entered into a research collaboration with the laboratory of Ellen Puré, Ph.D., professor/associate vice president for Academic Affairs at The Wistar Institute.

15 Apr 2011

Researchers discover new mechanism underlying esophageal cancer

A gene thought to be associated with cancer development can be a tumor suppressor gene in mice, researchers have discovered. Understanding which genes are involved in spreading cancer could lead to future therapies.

12 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Study shows, for the first time, the successful reprogramming of diseased human hepatocytes into induced pluripotent stem cells (iPSC).

1 Apr 2011

HIV uses base excision repair pathway to insert DNA into host-cell genome

The human immunodeficiency virus (HIV), the cause of AIDS, makes use of the base excision repair pathway when inserting its DNA into the host-cell genome, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Crippling the repair pathway prevents the virus from completing this critical step in the retrovirus's life cycle.

25 Mar 2011

Scientists discover hormone pathway that can lead to new diabetes treatment

Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.

25 Mar 2011

Study finds IL-13 stimulates airway fibroblast invasion in asthma patients

Changes that occur in the airways of asthma patients are in part caused by the naturally occurring protein interleukin-13 which stimulates invasion of airway cells called fibroblasts, according to a study conducted by researchers at Duke University.

23 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Fibrocell Science submits azficel-T final study report to FDA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a final study report to the U.S. Food & Drug Administration (FDA) for a completed, six-month histological study examining skin after injections of azficel-T.

16 Mar 2011

UCLA, Fibrocell Science enter scientific collaboration to advance cell therapy

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.

9 Mar 2011

Fibroblast News and Research

Further Reading